1311 related articles for article (PubMed ID: 30386104)
21. A new look at anti-Helicobacter pylori therapy.
Chuah SK; Tsay FW; Hsu PI; Wu DC
World J Gastroenterol; 2011 Sep; 17(35):3971-5. PubMed ID: 22046084
[TBL] [Abstract][Full Text] [Related]
22. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Quinolone-Containing Rescue Therapies After the Failure of Non-Bismuth Quadruple Treatments for Helicobacter pylori Eradication: Systematic Review and Meta-Analysis.
Marin AC; Nyssen OP; McNicholl AG; Gisbert JP
Drugs; 2017 May; 77(7):765-776. PubMed ID: 28361211
[TBL] [Abstract][Full Text] [Related]
24. High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures.
Goh KL; Manikam J; Qua CS
Aliment Pharmacol Ther; 2012 May; 35(9):1097-102. PubMed ID: 22404486
[TBL] [Abstract][Full Text] [Related]
25. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Cao Z; Chen Q; Zhang W; Liang X; Liao J; Liu W; Xiao S; Lu H
Scand J Gastroenterol; 2015; 50(10):1185-90. PubMed ID: 25881966
[TBL] [Abstract][Full Text] [Related]
26. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Fallone CA; Chiba N; van Zanten SV; Fischbach L; Gisbert JP; Hunt RH; Jones NL; Render C; Leontiadis GI; Moayyedi P; Marshall JK
Gastroenterology; 2016 Jul; 151(1):51-69.e14. PubMed ID: 27102658
[TBL] [Abstract][Full Text] [Related]
27. Second-line therapy with levofloxacin after failure of treatment to eradicate helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients.
Gisbert JP; Pérez-Aisa A; Bermejo F; Castro-Fernández M; Almela P; Barrio J; Cosme A; Modolell I; Bory F; Fernández-Bermejo M; Rodrigo L; Ortuño J; Sánchez-Pobre P; Khorrami S; Franco A; Tomas A; Guerra I; Lamas E; Ponce J; Calvet X;
J Clin Gastroenterol; 2013 Feb; 47(2):130-5. PubMed ID: 22647827
[TBL] [Abstract][Full Text] [Related]
28. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Bang CS; Lim H; Jeong HM; Shin WG; Choi JH; Soh JS; Kang HS; Yang YJ; Hong JT; Shin SP; Suk KT; Lee JJ; Baik GH; Kim DJ
Gut Microbes; 2020 Sep; 11(5):1314-1323. PubMed ID: 32362221
[TBL] [Abstract][Full Text] [Related]
29. Two-week, high-dose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments.
Gisbert JP; Romano M; Molina-Infante J; Lucendo AJ; Medina E; Modolell I; Rodríguez-Tellez M; Gomez B; Barrio J; Perona M; Ortuño J; Ariño I; Domínguez-Muñoz JE; Perez-Aisa Á; Bermejo F; Domínguez JL; Almela P; Gomez-Camarero J; Millastre J; Martin-Noguerol E; Gravina AG; Martorano M; Miranda A; Federico A; Fernandez-Bermejo M; Angueira T; Ferrer-Barcelo L; Fernández N; Marín AC; McNicholl AG
Dig Liver Dis; 2015 Feb; 47(2):108-13. PubMed ID: 25454706
[TBL] [Abstract][Full Text] [Related]
30. [Helicobacter pylori-associated diseases].
Gisbert JP
Gastroenterol Hepatol; 2015 Sep; 38 Suppl 1():39-48. PubMed ID: 26520195
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
Chuah SK; Tai WC; Hsu PI; Wu DC; Wu KL; Kuo CM; Chiu YC; Hu ML; Chou YP; Kuo YH; Liang CM; Chiu KW; Hu TH
Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
[TBL] [Abstract][Full Text] [Related]
32. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
33. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
34. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Luther J; Higgins PD; Schoenfeld PS; Moayyedi P; Vakil N; Chey WD
Am J Gastroenterol; 2010 Jan; 105(1):65-73. PubMed ID: 19755966
[TBL] [Abstract][Full Text] [Related]
35. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen.
Rokkas T; Sechopoulos P; Robotis I; Margantinis G; Pistiolas D
Am J Gastroenterol; 2009 Jan; 104(1):21-5. PubMed ID: 19098844
[TBL] [Abstract][Full Text] [Related]
36. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Branquinho D; Almeida N; Gregório C; Cabral JE; Casela A; Donato MM; Tomé L
BMC Gastroenterol; 2017 Feb; 17(1):31. PubMed ID: 28202013
[TBL] [Abstract][Full Text] [Related]
37. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis.
Li Y; Huang X; Yao L; Shi R; Zhang G
Wien Klin Wochenschr; 2010 Jul; 122(13-14):413-22. PubMed ID: 20628905
[TBL] [Abstract][Full Text] [Related]
38. 'Rescue' therapies for the management of Helicobacter pylori infection.
Di Mario F; Cavallaro LG; Scarpignato C
Dig Dis; 2006; 24(1-2):113-30. PubMed ID: 16699270
[TBL] [Abstract][Full Text] [Related]
39. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
[TBL] [Abstract][Full Text] [Related]
40. Helicobacter pylori eradication therapy.
Suzuki H; Nishizawa T; Hibi T
Future Microbiol; 2010 Apr; 5(4):639-48. PubMed ID: 20353303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]